Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma

Study Overview
=================
Brief Summary
-----------------
This trial is a multicentric study aiming to assess the evolution of the serum ifosfamide concentrations and its serum metabolites in patients treated for an Soft Tissue Sarcoma and co-exposed to Aprepitant. The study will be conducted on a population of patients treated with Doxorubicin and Ifosfamide. The Aprepitant can be prescribed to patients from cycle 2, according to the current recommendations. Doxorubicin, Ifosfamide and Aprepitant will be administered in the context of routine care. The follow-up during the treatment period and the clinical, biological and radiological assessments will be performed according to the standard of each centre. Patients will be followed during the two first cycles of treatment. For the pharmacokinetic study, blood samples will be collected at different time points during the 2 treatment cycles.

Official Title
-----------------
Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma

Conditions
-----------------
Soft Tissue Sarcoma

Intervention / Treatment
-----------------
* Drug: Patients starting a treatment with Doxorubicin and Ifosfamide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years. Anatomopathologic diagnosis of soft tissue sarcoma (localized, local recidive or metastatic). Patient receiving doxorubicin and ifosfamide chemotherapy (treatment decided during Multidisciplinary consultation meetings) (neoadjuvant, adjuvant or palliative treatment). Screening laboratory values must meet the following criteria: Hemoglobin > 9.0 g/dL, Neutrophils > 1500/mm3, Platelets > 100000/mm3 Creatinine clearance (MDRD formula) > 60ml/min. AST/ALT < 2.5 x ULN (5 x ULN in patients with hepatic metastasis). Evaluable disease (measurable per RECIST or not), if applicable. Patient must provide written informed consent prior to any study specific procedures. Patient affiliated to a Social Health Insurance in France. Exclusion Criteria: Previous treatment with Ifosfamide. Patient who has already started doxorubicin and ifosfamide treatment. Any medical condition that can increase the patient's risk Active infection Active hepatitis or cirrhosis Recipients of organ transplants or immunocompromised patients, including Human Immunodeficiency Virus (HIV) infection Pregnant or breastfeeding women Any psychological, familial, geographical or sociological condition which does not allow to respect the medical follow-up and/or compliance to study procedure Patient protected by law

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Patients starting a treatment with Doxorubicin and Ifosfamide<br> | Drug: Patients starting a treatment with Doxorubicin and Ifosfamide<br>* 9 blood samples will be collected at each Cycle: Cycle 1 (Day 1-Day 2-Day 3) Cycle 2 (Day 1-Day 2-Day 3)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evolution of 2d-Ifo plasma concentrations between the 1st cycle (without co-exposure to the Aprepitant) and the 2nd cycle (with co-exposure to the Aprepitant) |  | Cycle 2 Day 3 for each patient | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Toxicity assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 |  | Cycle 3 Day 1 for each patient | 
| Evolution of plasma concentrations of ifosfamide and its serum metabolites between the first and second cycles |  | Cycle 3 Day 1 for each patient | 
| The rate of objective responses determined according to the criteria RECIST v 1.1 |  | Cycle 3 Day 1 for each patient | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Soft Tissue Sarcoma, Ifosfamide, Aprepitant, Doxorubicin